Doyle Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Doyle Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-300	Closed	-$26K	–	264
2019 Q2	$26K	Buy	+300	New	+$25.7K	﹤0.01%	467
2019 Q1	–	Sell	-300	Closed	-$26K	–	252
2018 Q4	$26K	Buy	+300	New	+$28.5K	﹤0.01%	472

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Doyle Wealth Management's BMRN Position: Q3 2019 in Review

Doyle Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 300 shares — an estimated $26K sold.

Doyle Wealth Management first reported a position in BMRN in Q4 2018 and held it in 2 quarters. The position peaked at $26K in Q2 2019. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Doyle Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Doyle Wealth Management sold 300 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $26K.
Doyle Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Doyle Wealth Management's BioMarin Pharmaceuticals position peaked at $26K in Q2 2019.
436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Doyle Wealth Management's 13F filing for Q3 2019, filed 5 Nov 2019.